Evidence map›Paper›PMID 26599989›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2016

Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry.

Katherine J Nicholas, Allison R Greenplate, David K Flaherty, Brittany K Matlock, Juan San Juan, Rita M Smith, Jonathan M Irish, Spyros A Kalams

Open access · greenAbstract readComparative Study
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Multiparameter analysis of human B lymphocytes identifies heterogeneous CD19Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023
    Article
  6. OMIP-087: Thirty-two parameter mass cytometry panel to assess human CD4 and CD8 T cell activation, memory subsets, and helper subsets.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023
    Article
  7. Review
  8. Multiplatform Single-Cell Analysis Identifies Immune Cell Types Enhanced in Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2022
    Article
  9. A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022
    Review
  10. CyTOFFrontiers in immunology · 2022
    Review
  11. Article
  12. Article
  13. High-Dimensional Data Analysis Algorithms Yield Comparable Results for Mass Cytometry and Spectral Flow Cytometry Data.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Tolerating Factor VIII: Recent Progress.Frontiers in immunology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Katherine J NicholasDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Allison R GreenplateDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.
David K FlahertyFlow Cytometry Shared Resource, Vanderbilt University School of Medicine, Nashville, Tennessee.
Brittany K MatlockFlow Cytometry Shared Resource, Vanderbilt University School of Medicine, Nashville, Tennessee.
Juan San JuanDivision of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee.
Rita M SmithDivision of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee.
Jonathan M IrishDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Spyros A KalamsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Vanderbilt University · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Vanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
Vaccination design based on natural env genes to elicit broad neutralizing AbsP01AI078064 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HAIGWOOD, NANCY L · 2009 to 2014
$12.1M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
PARTNERS/FENWAY/SHATTUCK CENTER FOR AIDS RESEARCHP30AI042851 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2000 to 2003
$5.7M
Targeting the B Cell Receptor Signaling Network in LymphomaR00CA143231 · NCI · VANDERBILT UNIVERSITY · PI IRISH, JONATHAN MICHAEL · 2012 to 2014
$715k
Dissecting Mechanisms of Immunotherapy Response in Patients with MelanomaF31CA199993 · NCI · VANDERBILT UNIVERSITY · PI GREENPLATE, ALLIE · 2015 to 2017
$79k
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1TR000445NCI NIH HHS F31 CA199993NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS R00 CA143231NIAID NIH HHS P01 AI078064NIAID NIH HHS P30 AI042851NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI110527NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI069439NIDDK NIH HHS P30 DK058404PHS HHS P01A1078064
6 · The paper itself

Abstract

Mass and fluorescence cytometry are quantitative single cell flow cytometry approaches that are powerful tools for characterizing diverse tissues and cellular systems. Here mass cytometry was directly compared with fluorescence cytometry by studying phenotypes of healthy human peripheral blood mononuclear cells (PBMC) in the context of superantigen stimulation. One mass cytometry panel and five fluorescence cytometry panels were used to measure 20 well-established lymphocyte markers of memory and activation. Comparable frequencies of both common and rare cell subpopulations were observed with fluorescence and mass cytometry using biaxial gating. The unsupervised high-dimensional analysis tool viSNE was then used to analyze data sets generated from both mass and fluorescence cytometry. viSNE analysis effectively characterized PBMC using eight features per cell and identified similar frequencies of activated CD4+ T cells with both technologies. These results suggest combinations of unsupervised analysis programs and extended multiparameter cytometry will be indispensable tools for detecting perturbations in protein expression in both health and disease.

Indexed as

Antigens, CDFlow CytometryGene ExpressionHumansImmunophenotypingLanthanoid Series ElementsLeukocytes, MononuclearLymphocyte ActivationMass SpectrometryMultivariate AnalysisAntigens, CDLanthanoid Series ElementsCyTOFfluorescence cytometryhuman PBMCmass cytometryT cellsviSNE

Identifiers

PMID26599989
PMCPMC4808335
OpenAlexW2176701861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.